I found that part extremely interesting as well.

I found that part extremely interesting as well. I interpret that the "potential benefits" must be pretty good in order to keep the trial open. Especially since it looks like CTIX will now have to take an extra step and request the phase 2 study be allowed to advance since the phase 1 is not officially closed. That might not be a big deal, but it is still another item the FDA must process and with more paperwork there is always additional lead time to get it finalized and approved. There must really be some significant value in acquiring more data, because it is obvious that there is significant value in helping the very sick patients fight their disease.
K is going to be a monster. I can't help but continue to be curious as to where in the process the peer reviewed article is. We have not heard anything about that in the last 5 plus months, have we? That will be a sweet surprise PR to drop unexpectedly: "Peer reviewed article on Kevetrin to be published in the New England Journal of Medicine". I like the sound of that.